喘可治注射液联合多索茶碱治疗慢性阻塞性肺疾病急性发作期的疗效观察

目的探讨喘可治联合多索茶碱治疗慢性阻塞性肺疾病急性发作期的临床疗效。方法选取2016年6月—2017年6月在西宁市第三人民医院治疗的慢性阻塞性肺疾病急性发作期患者166例,随机分成对照组和治疗组,每组各83例。对照组患者静脉滴注注射用多索茶碱,0.2 g加入5%葡萄糖注射液100 mL,1次/d;治疗组在对照组基础上肌肉注射喘可治注射液,4 mL/次,2次/d。两组患者均连续用药7 d。观察两组患者临床疗效,比较治疗前后两组患者主要临床症状消失时间和住院时间及肺功能指标。结果治疗后,对照组和治疗组临床总有效率分别为86.75%和97.59%,两组比较差异具有统计学意义(P0.05)。治疗后,治疗组患者呼吸困难症状消失时间、咳嗽消失时间和住院时间均显著短于对照组患者,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者肺功能指标第一秒用力呼气容积(FEV1)、最大呼气流量(PEF)和FEV1/FVC均显著升高,同组比较差异具有统计学意义(P0.05);且治疗组患者的肺功能指标显著高于对照组患者,两组比较差异具有统计学意义(P0.05)。结论喘可治联合多索茶碱治疗慢性阻塞性肺疾病急性发作期患者临床疗效显著,安全性好,具有一定的临床推广应用价值。

Clinical observation of Chuankezhi Injection combined with doxofylline in treatment of acute exacerbation of chronic obstructive pulmonary disease

Objective To investigate the clinical efficacy of chuankezhi combined with doxofylline in treatment of acute exacerbation of chronic obstructive pulmonary disease. Methods Patients (166 cases) with acute exacerbation of chronic obstructive pulmonary disease in the Third People''s Hospital of Xining from June 2016 to June 2017 were randomly divided into control and treatment groups, and each group had 83 cases. Patients in the control group were iv administered with Doxofylline for injection, 0.2 g added into 5% glucose injection 100 mL, once daily. Patients in the treatment group were im administered with Chuankezhi Injection on the basis of the control group, 40 mL/time, twice daily. Patients in two groups were treated for 7 d. After treatment, the clinical efficacy was evaluated, and the disappearance time of clinical symptoms and hospitalization time, the pulmonary function indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 86.75% and 97.59%, respectively, and there were differences between two groups (P < 0.05). After treatment, the disappearance time of dyspnea and cough, the hospitalization time in the treatment group was significantly less than that in the control group, with significant difference between two groups (P < 0.05). After treatment, the FEV1, PEF and FEV1/FVC in two groups were significantly increased, and there were differences in the same group (P < 0.05). And the pulmonary function indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P < 0.05). Conclusion chuankezhi combined with doxofylline has significant clinical efficacy in treatment of acute exacerbation of chronic obstructive pulmonary disease with higher safety, which has a certain clinical application value.